Evolve is a new kind of biologics company founded for a clear purpose: bringing critical plasma proteins to the people who need them.
Evolve is a new kind of biologics company. We’re built around a next-generation technology for bringing critical therapeutics to the people who need them.
People with many rare diseases rely on therapies made from proteins extracted from blood plasma. For more than 75 years, these proteins have been captured through a largely unchanged yet expensive process. Until now.
We believe our patented next-generation technology, PlasmaCap EBA®, is the first major advancement in the field since the 1940s. We believe it will help us deliver critical plasma-derived therapeutics at higher levels of purity, efficiency, and quality than conventional methods can.
Ultimately, Evolve aims to improve the lives of people within a largely underserved market—building a broad and innovative product portfolio in the process.
Vision
We believe we can deliver plasma-derived therapeutics at higher levels of purity, efficiency, and reliability than anyone in our industry currently delivers.
As a first step toward achieving that vision, we have advanced the technology used to extract plasma proteins from blood. We believe our patented technique, PlasmaCap EBA®, is the first major innovation in this area in more than 75 years.
We believe this technique will allow us to advance the quality of plasma-derived therapeutics. It has the potential to extract more value from each liter of precious donor plasma as compared to legacy technology.
And this efficiency drives reliability—in both quality and consistency of supply. Because our technology is proprietary and protected, and we have direct control of our manufacturing, we expect our supply to be more consistent and predictable than today’s options.
We think it’s about time someone advanced the way biologics are delivered. So Evolve is doing just that.
Milestones
Evolve may be a new company, but the essence of our story stretches back decades—and it will continue to be written for years to come.
Leadership
We’re led by a proven executive team.
Our experienced and passionate leaders have spent decades honing their expertise across leading pharmaceutical and biologics organizations.
Nick Green
Nick currently serves as President & CEO of Therapure Biopharma Inc. of which Evolve Biologics is a division, and previously served in senior executive roles for several contract manufacturing organizations and life sciences companies, including Managing Director of Nipa Laboratories Ltd, Head of the Life Sciences Division of Clariant International Ltd, President and CEO of Rhodia Pharma Solutions and President of Codexis Pharma Division. Nick is also a current Board Member at Induce Biologics Inc.
Since starting his career in a family owned-business, Nick has developed a diverse global pharmaceutical background, spanning four continents and running a total of 31 facilities in nine countries. Nick holds a BSc (Hons) in Chemistry from Queen Mary University of London and an MBA from the University of Huddersfield in the UK.
David Holliday
With over 30 years of pharmaceutical and biologics experience, David has held progressively senior commercial roles in both private and public companies.
He has successfully launched and commercialized a number of key >$1B biologics in the United Kingdom, United States, and other global markets, most recently, as VP Commercial Operations for Octapharma US. Prior to Octapharma US, he was Global Vice President of Marketing Operations and Hemophilia for Baxter (now Shire) and also led their Bioscience business in the UK, following a 17-year career with Novartis. David holds a DMS from Kingston University in London.
Mark Krause
Mark served as Head of Plasma Proteins at Therapure Biopharma Inc. from 2011 until the formation of Evolve Biologics.
He previously held progressively senior positions within the finance operations at Valeant (formerly Biovail). As Director, Financial Analysis and Planning, Mark worked closely with business development, R&D, and manufacturing, particularly during licensing transactions. Mark earned both a BSc in biology from the University of British Columbia and an MBA from Richard Ivey School of Business, and is a Certified Professional Accountant.